|
|
|
|
| LEADER |
02677nmm a2200313 u 4500 |
| 001 |
EB001873412 |
| 003 |
EBX01000000000000001036783 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
190924 ||| eng |
| 020 |
|
|
|a 9783030190194
|
| 100 |
1 |
|
|a Nanni, Cristina
|e [editor]
|
| 245 |
0 |
0 |
|a Molecular Imaging in Multiple Myeloma
|h Elektronische Ressource
|c edited by Cristina Nanni, Stefano Fanti, Lucia Zanoni
|
| 250 |
|
|
|a 1st ed. 2019
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2019, 2019
|
| 300 |
|
|
|a V, 136 p. 57 illus., 38 illus. in color
|b online resource
|
| 505 |
0 |
|
|a 1.Multiple Myeloma: clinical aspects -- 2. What does a clinician need from new imaging procedures? -- 3.FDG PET in Multiple Myeloma -- 4. Role of Standard Magnetic Resonance Imaging -- 5.Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A new era for whole body imaging in myeloma? -- 6.CXCR4 imaging in Multiple Myeloma -- 7.PET/CT with Standard NON-FDG Tracers -- 8. The issue of interpretation -- 9. Clinical Teachning Cases: FDG PET/CT
|
| 653 |
|
|
|a Nuclear Medicine
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Nuclear medicine
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Fanti, Stefano
|e [editor]
|
| 700 |
1 |
|
|a Zanoni, Lucia
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-3-030-19019-4
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-19019-4?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.0757
|
| 520 |
|
|
|a This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/orevaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists
|